Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
3.260
+0.082 (2.58%)
At close: May 12, 2025, 4:00 PM
3.100
-0.160 (-4.91%)
After-hours: May 12, 2025, 5:05 PM EDT
Revelation Biosciences Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Revelation Biosciences.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Revelation Biosciences.
Recommendation Trends
Rating | Dec '22 | Jan '23 | Feb '23 |
---|---|---|---|
Strong Buy | 1 | 1 | 0 |
Buy | 0 | 0 | 0 |
Hold | 0 | 0 | 0 |
Sell | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 |
Total | 1 | 1 | 0 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Roth MKM | Roth MKM | Strong Buy Maintains $2,400 → $7,200 | Strong Buy | Maintains | $2,400 → $7,200 | +220,758.90% | Feb 14, 2023 |
Roth Capital | Roth Capital | Strong Buy Initiates $201,600 | Strong Buy | Initiates | $201,600 | +6,183,949.08% | Feb 17, 2022 |
Financial Forecast
Revenue This Year
n/a
from 63.84M
Revenue Next Year
n/a
EPS This Year
-22.14
from -87.68
EPS Next Year
-2.96
from -22.14
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | n/a | n/a | n/a | ||
Avg | n/a | n/a | n/a | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -4.74 | -3.05 | -2.90 | ||
Avg | -22.14 | -2.96 | -2.82 | ||
Low | -38.12 | -2.84 | -2.70 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.